- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01076036
CorPath™ 200: Robotically-Assisted Percutaneous Coronary Intervention (PCI)
CorPath™ 200 System: Coronary Remote Catheterization Feasibility Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective The study objective was to evaluate the safety and technical efficacy of the CorPath 200 System in delivery and manipulation of commercially available coronary guidewires and rapid exchange balloon/stent catheter for use in percutaneous coronary interventions (PCI).
I. Primary Endpoints A. Efficacy Device Clinical Success: Achievement of a < 30% final diameter stenosis after utilizing the CorPathTM 200 System to deliver a PTCA balloon and then stent to the target lesion, and successfully retract the devices without the occurrence of any In-Hospital MACE (Major Adverse Cardiac Event) evaluated at 48 hours post procedure or hospital discharge, whichever occurs first.
B. Safety In-Hospital MACE: Defined as the composite of death (all cause mortality), recurrent MI, and target vessel revascularization (emergent coronary artery bypass surgery [CABG] or PCI) evaluated at 48 hours post procedure or hospital discharge, whichever occurs first.
II. Secondary Endpoints A. Efficacy CorPath Success: Ability to navigate the guide wire and balloon/stent system utilizing the CorPath™ device to the target site without the occurrence of any In-Hospital MACE, evaluated at 48 hours post index procedure or hospital discharge, whichever occurs first.
Subject Clinical Success: Achievement of a <30% final diameter stenosis of target lesion after treatment with PTCA/coronary stent without the occurrence of any In-Hospital MACE, evaluated at 48 hours post-index procedure or hospital discharge, whichever occurs first.
B. Safety:
MACE at 30 Days: Defined as the composite of death, recurrent MI and/or target vessel revascularization (emergent coronary artery bypass surgery [CABG] or PCI) evaluated at 30 days post index procedure.
Adverse Events:
A summary of all adverse events observed in the trial summarized as either serious or non-serious and summarized by attribution.
C. Clinical Utility
Procedure Attributes:
- Reduction in radiation exposure to the primary operator based on radiation dosimetry measurements at the procedure table and on a primary operator.
- Total Procedure time based on the time of insertion of hemostasis sheath through the time of final guide catheter withdrawal.
CorPath Device Attributes:
Subjective assessment by the operator of the following device performance attributes:
- Movement of the guide wire (rotating and advancing) to the target.
- Maneuvering and position of the guide wire to the target.
- Movement of the stent/balloon (advancing) to the target.
- Ability to deliver the PTCA/stent system to the intended target lesion.
- Ease of use of the system by the interventional team.
Material & Methods Corindus obtained approval (from the CORBIC Ethics Committee and INVIMA - Colombian Ministry of Health) in 2009 to conduct the clinical study "CorPath™ 200 System: Coronary Remote Catheterization Feasibility Study" at CORBIC Cardio-Neuro-Vascular Institute, Envigado, Colombia.
The study is a single arm, open label, prospective registry to treat a de novo lesion (2.5 mm - 4.0 mm in diameter, 25.0 mm in length with >50% stenosis) utilizing the CorPath 200 System to deliver, manipulate and retrieve a guidewire and a balloon/stent catheter system.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Medellin, Colombia
- CORBIC Cardio-Neuro-Vascular Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
General Inclusion Criteria:
- The subject is an acceptable candidate for PCI.
- The subject must have clinical evidence of ischemic heart disease or a positive functional study.
- Female subjects must be of non-child bearing potential, or if able to bear children, have a negative pregnancy test within seven (7) days prior to index procedure.
- The subject or the legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.
Angiographic Inclusion Criteria:
- Study lesion is de novo native coronary artery lesion (i.e., a coronary lesion not previously treated)
- The study lesion is intended to be treated with one stent. Maximum stent length allowed is 20 mm.
- The study reference vessel diameter is between 2.50 mm and 4.5 mm by visual estimate.
- Study lesion diameter showing significant stenosis of at least 50% by visual estimate.
General Exclusion Criteria:
- Subject requires planned PCI or CABG within 30 days following the index procedure.
- Subject has evolving ST elevation myocardial infarction (STEMI) (i.e., beginning of MI symptoms within 72 hours prior to the planned index procedure).
- Subject has documented left ventricular ejection fraction < 30%.
- Subject has known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, stainless steel, or a sensitivity to contrast media, which cannot be adequately pre-medicated.
- Subject has a platelet count < 100,000 cell/mm3 or > 700,000 cell/ mm3, a WBC of < 3000 cell/ mm3 (e.g. thrombocytopenia, thrombocythemia, neutropenia or leucopenia).
- Subject has a history of a stroke (CVA) or TIA within 30-days prior to planned index procedure.
- Subject has an active peptic ulcer or upper GI bleeding within the 6 months prior to planned index procedure.
- Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
- Subject is currently participating in another investigational drug l drug or device trial that has not completed the entire follow up period.
Angiographic Exclusion Criteria:
- Study lesion that cannot be fully covered by a single stent of maximal length
- Subject requires treatment of multiple lesions in the study vessel at the time of index procedure.
- The study lesion requires planned treatment with DCA, laser, rotational atherectomy, or any device except for balloon dilatation prior to stent placement.
- The study vessel has evidence of intraluminal thrombus or moderate to severe tortuosity (> 90o) proximal to the target lesion.
The study lesion has any of the following characteristics:
- Total occlusion
- Ostial location
- Involves a side branch > 2.0 mm vessel diameter
- Is located at >45° bend in the vessel
- Is moderately to severely calcified
- Moderate-to-severe calcification at the part of the vessel prior to target lesion
- Unprotected left main coronary artery disease (an obstruction greater than 50% diameter stenosis in the left main coronary artery).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CorPath 200 System
Robotic-assisted PCI with the CorPath 200
|
CorPath™ 200 robotically-assisted percutaneous coronary intervention
CorPath PCI - robotic-assisted percutaneous coronary intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Procedural Success
Time Frame: 48-hrs or hospital discharge, whichever occurs first
|
The percentage of Participants with <30% final diameter stenosis of the target lesion without in-hospital major adverse cardiovascular events (MACE) (defined as the composite of death, recurrent MI, and target vessel revascularization)
|
48-hrs or hospital discharge, whichever occurs first
|
Procedural Technical Success
Time Frame: Intervention
|
Successful robotic delivery and retraction of all PCI devices during CorPath PCI procedure.
|
Intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Juan F Granada, MD, CORBIC and CRF
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Corindus-Corbic-2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on CorPath 200
-
Corindus Inc.CompletedPeripheral Arterial DiseaseAustria
-
Corindus Inc.CompletedMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis | Arterial Occlusive DiseasesUnited States, Colombia
-
Corindus Inc.Terminated
-
Corindus Inc.CompletedHeadache | Subarachnoid Hemorrhage | Intracranial AneurysmCanada, Spain, Australia, Switzerland, Austria, France
-
Clinical Research Center, Intercard Sp. z o.o.Corindus, Inc. dba Siemens Healthineers Endovascular Robotics; KCRI Sp. z o.o.Recruiting
-
Corindus Inc.CompletedMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Vascular Diseases | Coronary Artery Disease | Coronary Disease | Arteriosclerosis | Arterial Occlusive DiseasesUnited States, Israel
-
Corindus Inc.TerminatedCoronary Artery Disease | Percutaneous Coronary Intervention | Chronic Total Occlusion of Coronary ArteryUnited States
-
Corindus Inc.Completed